分子标记物在胆管癌早期诊断及评估预后中的研究进展  

Novel diagnostic and prognostic biomarkers in cholangiocarcinoma

作　　者：方天逸 王宇夫 林轩 王浩[1] 崔云甫[1] Fang Tianyi;Wang Yufu;Lin Xuan;Wang Hao;Cui Yunfu(Department of Hepatopancreatobiliary Surgery,the Second Affiliated Hospital of Harbin Medical University,Harbin 150081,China)

机构地区：[1]哈尔滨医科大学附属第二医院胆胰外科,150081

出　　处：《国际遗传学杂志》2018年第5期371-377,共7页International Journal of Genetics

基　　金：国家自然科学基金（81170426）

摘　　要：胆管癌是一类起源于胆道上皮细胞的恶性肿瘤，其早期症状不典型，获得确定性诊断时往往已进入中晚期，预后不佳。临床常用的实验室检查方法难以在敏感性和特异性方面获得平衡。因此，寻找新的分子标记物，特别是可以便捷地从血液、胆汁及体液中获得的恰当的生物分子，对该病的临床诊治意义重大。随着基因组学、表观遗传学、转录组学、蛋白质组学、代谢组学和影像组学的飞速发展，胆管癌的研究也已进入了新的阶段，研究者已陆续发现了一些极有潜力的生物分子，有望应用于该病的早期诊断及预后评估。本文综述了目前已获得关注的胆管癌分子标记物，以期为未来的进一步研究及应用提供参考。Cholangiocarcinoma is a malignant tumor that originates from biliary epithelial cells. Its early symptoms are atypical. When a definitive diagnosis is achieved, it is often already at middle and late stages, and the prognosis is poor. It is difficult to obtain a balance between sensitivity and specificity in current laboratory tests. Therefore, the search for new molecular markers, especially suitable biomolecules that can be conveniently obtained from blood, bile and other body fluids, is of great significance for the clinical diagnosis and treatment of the disease. With the rapid development of genomics, epigenetics, transcriptomics, proteomics, metabolomics, and radiomics, these studies have entered a new phase. Researchers have discovered some potential biomolecules expected to be used for the early diagnosis and prognosis assessment of the disease. This article reviews the currently-obtained molecular markers of cholangiocarcinoma to provide reference for further research and application.

关 键 词：胆管癌 分子标记物 基因组学 表观遗传学 转录组学 蛋白质组学 代谢组学 影像组学 

分 类 号：R735.8[医药卫生—肿瘤]